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Abstract
Background: Nowadays there is a debate about the indication of the oral whole-cell/recombinant
B-subunit cholera vaccine (WC/rBS) in traveller's diarrhoea. However, a cost-benefit analysis based
on real data has not been published.
Methods: A cost-effectiveness and cost-benefit study of the oral cholera vaccine (WC/rBS),
Dukoral® for the prevention of traveller's diarrhoea (TD) was performed in subjects travelling to
cholera risk areas. The effectiveness of WC/rBS vaccine in the prevention of TD was analyzed in
362 travellers attending two International Vaccination Centres in Spain between May and
September 2005.
Results: The overall vaccine efficacy against TD was 42,6%. Direct healthcare-related costs as well
as indirect costs (lost vacation days) subsequent to the disease were considered. Preventive
vaccination against TD resulted in a mean saving of 79.26 € per traveller.
Conclusion: According to the cost-benefit analysis performed, the recommendation for WC/rBS
vaccination in subjects travelling to zones at risk of TD is beneficial for the traveller, regardless of
trip duration and visited continent.
Background
Travellers' diarrhoea (TD) is rather defined by circum-
stances of acquisition than by specific microbial agents.
TD is usually defined as the passage of 3 or more
unformed stools in a 24-hour period, or any number of
loose stools if accompanied by abdominal pain, fever,
nausea or vomiting. TD is the most frequent syndrome
among travellers in most of the visited regions and affects
20–60% of travellers [1]. Some authors have described
that 8% of travellers seek medical care upon their return;
of these, one third reports diarrhoeal diseases [2-5] TD
typically occurs during the first week after arrival, is often
self-limiting, and lasts three to four days. Only approxi-
mately 2–3% of TD persists longer than a month [1,6]
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Efforts to determine the etiology of travellers' diarrhoea in
returning travellers encounter several difficulties. Most
cases of travellers' diarrhoea are relatively mild and self-
limiting, and the patient may not visit a doctor to report
it. However, if the patient is ill enough to see a doctor,
stool samples are often not obtained for laboratory confir-
mation. And finally, if a sample is taken and analyzed, it
may be impossible to identify a responsible organism. In
fact, it has been estimated that only 1 in 136 cases of gas-
trointestinal infections in the UK is reported to routine
surveillance systems [7]. The most common cause of TD
worldwide is enterotoxigenic Escherichia Coli (ETEC),
which induce watery diarrhoea associated with cramps
and with low grade or absent fever [1]. ETEC infections are
common when there is a breakdown in sanitation, which
is often the case in developing countries [5]. Other bacte-
rial etiologies are Campylobacter (jejuni, coli), Salmonella,
Shigella, Vibrio cholerae, V. parahaemolyicus, V. vulnificus,
Yersinia enterocolitica, and Clostridium difficile [1,8].
Because most cases of cholera are mild or moderate [1,9-
11]., one part of TD contracted in cholera-endemic or epi-
demic countries may be cholera [12].
The most important determinant of risk is the travel desti-
nation. Regional differences in both the risk and etiology
of diarrhoea divide the world into three grades of risk
(high, intermediate, and low). High-risk areas include
most of Asia, the Middle East, Africa, and Central and
South America. Approximately 50,000 daily cases of TD
are estimated among the 50 million people travelling to
developing countries. More temperate regions involve
seasonal variations in diarrhoea risk. In South Asia, for
example, much higher TD attack rates are commonly
reported during the hot pre-monsoon months [4]
TD occurs equally in males and females, and is more com-
mon in young adults than in older people. Others risk fac-
tors for TD include anti-acid medications, achlorhydria,
hypoclorhydria, gastrectomy, type O blood, or immune
deficiency [6] In short-term travellers, bouts of TD do not
appear to protect against future attacks, and more than
one episode of TD may occur during a single trip. For trav-
ellers to high-risk areas, several approaches may be recom-
mended which can minimize, but never completely
eliminate, the risk of TD. The usual recommendations
about basic hygiene are usually quickly forgotten, and fol-
lowed only by a small number of travellers. Therefore,
besides these useful recommendations, complementary
actions for controlling these diseases -mainly transmitted
by contaminated water and food- should be considered
[13]
In Spain, preventive care of international travellers
(health education and vaccination) is mostly performed
through a network of 52 public International Vaccination
Centres (IVC). This network was visited by a total of
188,445 and 204,985 travellers during 2005 and 2006,
respectively [14]. IVC belong to a state-based network,
which performs travellers' care only. The consultations
peak is from the month of May to September. By late June
2005, the oral vaccine Dukoral® (whole-cell/recombinant
B-subunit cholera vaccine, WC/rBS) was marketed in
Spain subsequent to its authorization in the European
Union for the prevention of cholera, in April 2004 [15].
Dukoral® had previously been authorized in another 25
countries for the indication of both cholera and ETEC-
related diarrhoea, except in Australia, where it was author-
ized for cholera prevention only [16]. Several studies have
evidenced the efficacy of WC/rBS vaccine for protection
against diarrhoea caused by LT-related ETEC [17-19].
The objectives of this article were:
1. To assess the effectiveness of WC/rBS cholera vaccine in
the prevention of diarrhoea in subjects travelling to chol-
era endemic-epidemic zones and having attended the
Spanish network of IVC.
2. To perform economical (cost-effectiveness and cost-
benefit) analysis of WC/rBS vaccination in subjects travel-
ling to high-risk zones of TD, as compared to non-vacci-
nated subjects with a similar destination.
Methods
Vaccine effectiveness
This study was designed as a retrospective cohort study,
performed by means of a phone survey to 362 subjects
having travelled to zones at risk of cholera and TD.
The WC/rBS cholera vaccine is indicated in subjects trav-
elling for more than 7 days to cholera-endemic or epi-
demic countries, or else in shorter stays if the trip or the
traveller involves high-risk circumstances. Traveller's diar-
rhoea was considered to be any diarrhoeal process, as
defined in the introduction and perceived as such by the
traveller, occurring during a journey or within 7 days after
the return.
Non-vaccinated travellers were those attending the IVC
before the vaccine was marketed and available, or declin-
ing recommendation for vaccine, or failing to attend the
centre early enough for proper vaccination.
One cohort of cholera vaccinated subjects (N = 171) and
one cohort of non-vaccinated subjects (N = 191) travel-
ling to the same zones were studied. All subjects travelling
to cholera risk zones were selected consecutively, namely,
125 travellers (58 vaccinated and 67 non-vaccinated)
attending Santander's IVC between July and September
2005, and 237 travellers (113 vaccinated and 124 non-BMC Infectious Diseases 2009, 9:65 http://www.biomedcentral.com/1471-2334/9/65
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vaccinated) attending Málaga's IVC between May and Sep-
tember 2005. Neither the IVC attending staff nor the trav-
eller during his/her trip were aware of the possibility of
being part of a study. After obtaining consent of the trav-
ellers, they were interviewed by telephone regarding the
trip for which they attended the IVC: travel characteristics,
vaccine administration, possible TD occurrence, and cor-
responding treatment. The interviewer was different in
each IVC, being a worker of the same centre visited by the
traveller. The phone interview lasted 10 minutes on aver-
age per traveller, and all contacted travellers accepted and
were interested in taking part in the study (except for one
traveller of Santander's IVC). The designed questionnaire
contained 40 variables, focusing on personal data (age,
sex, medical history), trip details and, in vaccinated travel-
lers, confirming that they had taken Dukoral® correctly
and whether they experienced any side effect. The ques-
tionnaire also asked about TD occurrence during the trip
or within the week thereafter, its duration and severity,
whether any treatment or medical assistance was required,
and TD-related limitation of activity. The mean time inter-
val between the trip and the interview was 54 days (52%
were interviewed between two and four weeks after return,
30% between five and eight, and 18% between nine and
twenty two weeks), and there were no statistically signifi-
cant differences between vaccinated and non-vaccinated
travellers groups.
The possible bias derived from variability between the two
observers was assessed by means of a concordance study.
The kappa's index obtained for the TD presence/absence
variable was 0.859 (95% CI: 0.591–1.126), correspond-
ing to a 'perfect' or 'substantial' agreement according to
the six-category system proposed by Landis and Koch
[20].
Economic analysis (cost-effectiveness and cost-benefit)
Model description
The cost and the benefits of the cohort vaccinated against
cholera (N = 171) were compared with those of the non-
vaccinated cohort (N = 191). Economic analysis was car-
ried out from the healthcare provider's perspective (cost-
effectiveness analysis) and from the social perspective
(cost-benefit analysis). When analysis was carried out
from the provider's perspective, only direct costs and ben-
efits were included. When analysis was done from the
social perspective, direct and indirect costs and benefits
were included.
The time horizon of the programme was established in 7
months. Such a short time horizon makes unnecessary to
apply a discount rate to the costs and benefits. All costs
and benefits were expressed in 2005 euros.
To analyze disease evolution with and without the vacci-
nation programme, a decision tree was designed to
include all possible events. When the net present value
was > 0 the vaccination was considered as money-saving
and therefore the cost-effectiveness ratio (being < 0) was
not calculated. If the net present value was < 0, a cost-
effectiveness analysis was performed.
Health care cost
All travellers included in the study received healthcare at
the IVCs. The cost of healthcare provided at the IVCs was
estimated from the figure published by the WHO as cost
per visit to health centre by Spanish populations residing
within 1 hour of the centre (21.57 € of the year 2000)
[21]. This figure was updated to 2005 by means of annual
CPI (24.90 €). In travellers not vaccinated with WC/rBS,
only healthcare cost (24.90 €) was applied.
Vaccination cost
The travellers of the vaccinated cohort received two oral
doses of the WC/rBS vaccine with a minimum interdose
interval of one week. The cost of the two doses of vaccine
was 32.31 €.
Cost of disease in vaccinated and non-vaccinated subjects
Direct costs
- Cost of TD treatment: As established by WHO [22], and
depending on TD severity, mild cases only require Oral
Rehydration Salts (ORS). If unresolved, antibiotics (qui-
nolones or Azithromycin) and antiperistaltics (Lopera-
mide) are added. Treatment with Loperamide (10
capsules, 3.21 €), Azithromycin (3 tablets, 9.68 €) or the
recent alternative of Rifaximin (12 tablets, 9.61 €), and
Oral Rehydration Salts (5 sachets, 2.33 €, to prepare 5 lit-
ers of serum for 2 days of treatment) was assessed as fol-
lows:
- Mild TD: ORS (€ × days of TD duration)
- Moderate TD: Loperamide (3.21 €) + Azithromycin or
Rifaximin (9.61 €) + ORS (€ × days of TD duration)
The hypothesized cost difference between vaccinated and
non-vaccinated subjects lies in the difference of TD dura-
tion observed in previous studies [23].
Indirect costs
The cost for TD-related lost vacation days is derived from
the average cost of 1 vacation day in a organized trip:
142.86 €. This figure results from dividing 3000 € by 21
days (mean cost of a 3-week trip, as usually performed by
the study travellers).BMC Infectious Diseases 2009, 9:65 http://www.biomedcentral.com/1471-2334/9/65
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Statistical analysis
The data were processed and analyzed using the Statistical
Package for the Social Sciences (SPSS) v.17 (SPSS Inc.,
Chicago, IL, USA).
Ethical considerations
Our study was supervised by the Ethics committee of the
University of Malaga.
Results
Effectiveness of WC/rBS cholera vaccine (Dukoral) in the 
prevention of TD
All interviewed travellers from vaccinated cohorts took the
vaccine properly, and none reported drug-related side
effects.
The main findings observed in each Centre's individual
analyses are consistent with those obtained by summing
the data of both IVC, which are presented below.
1. The frequency of TD in the vaccinated and non-vacci-
nated travellers groups was 21.1% and 36.6%, respec-
tively, being the difference statistically significant (p =
0.001). This corresponds to a risk difference (RD) of 0.16
(95% CI: 0.07–0.25) and a number needed to treat (NNT)
of 6.25 (95% CI: 4–14.3). The relative risk (RR), as a
measure of protection against TD, was 0.57 (95% CI:
0.41–0.81). Overall vaccine efficacy was 42.6% (95% CI:
18.9–59.3), with no differences found between the two
IVCs (42.9% and 42.5% in Málaga and Santander, respec-
tively).
2. Among vaccinated subjects, TD lasted 1 or 2 days in
72.2% of them and 3 or more days in the remaining
27.8%; while TD duration in non-vaccinated subjects was
of 2 days at most in 45.7% of them and longer in the
remaining 54.3% (p = 0.009). The mean duration of TD
was 2.57 days and 3.59 days in vaccinated and non-vacci-
nated subjects, respectively.
3. The differences in TD frequency were more relevant in
trips to Africa, with TD incidence in vaccinated and non-
vaccinated subjects of 16% and 32%, respectively (p =
0.009; Table 1).
4. The protective effect of the vaccine against TD was
maintained regardless of trip duration (Table 1). How-
ever, vaccine efficacy was somewhat higher in trips of less
than 21 days. No significant differences in the vaccine effi-
cacy concerning the time lapse between the return and the
interview were found.
5. In order to assess the possible confounding effect of
these variables on the relationship between vaccination
and TD, a multivariate analysis by logistic regression was
performed. For that purpose, 2 categories were considered
for traveller's age (between 30 and 44 years, vs. 45 or
older), trip duration (20 days or less vs. 21 days or
longer), IVC (Málaga vs. Santander), and visited region
(Africa vs. other regions). The estimated non-adjusted
effect yields an OR of 0.45 (95% CI 0.27–0.73), i.e. a glo-
bally protective value. The model that best fits the data
includes trip duration as a covariate, and shows that the
protective effect of vaccination against TD is slightly
increased when adjusted by it (OR = 0.42, 95% CI 0.26–
0.69).
Cost-effectiveness analysis of vaccine recommendation to 
subjects travelling to zones at high risk of TD
The prevention of traveller's diarrhoea is the assessed
effect.
Cost analysis was performed from the perspective of the
health care system. Programme costs are all those associ-
ated to the use of health technology and involving sacri-
fice of resources for either the health sector or the patient
him/herself.
Table 1: TD frequency and vaccine efficacy (VE) according to destination, age, and trip duration, in vaccinated and non-vaccinated 
subjects.
Vaccinated Non-vaccinated
N TD (%) N TD % p value VE (%)
Destination
Africa 100 16.0 90 32.2 0.009 50.3
C and S America 27 29.6 38 36.8 0.545 19.6
South East Asia 44 27.3 63 42.9 0.099 36.4
Age (years)
< 30 54 24.1 50 54.0 0.002 55.4
30–45 77 24.7 99 31.3 0.212 21.2
> 45 40 10.0 42 28.6 0.031 65.0
Trip duration (Weeks)
< 3 83 16.9 124 33.1 0.010 49.0
≥ 3 88 25.0 67 43.3 0.016 42.2BMC Infectious Diseases 2009, 9:65 http://www.biomedcentral.com/1471-2334/9/65
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TD treatment costs have been calculated based on the cost
ratio detailed in the 'Material and Methods' section. In the
whole sample, 93% of travellers with TD deemed it as
'mild', while only 7% considered it was 'moderate'. None
of the interviewed travellers with TD deemed it as 'severe'.
No differences in this perception of TD intensity were
found between the vaccinated and non-vaccinated
cohorts. Treatment costs were calculated according to
these ratios.
1.-Treatment of mild TD (93% of subjects with TD) with
ORS alone: 2.33 € for each vaccinated subject (5 liters of
ORS) and 4.66 € for each non-vaccinated subject (10 lit-
ers of ORS).
2.-Treatment of moderate TD (7% of subjects with TD)
with ORS + Azithromycin or Rifaximin + Loperamide:
15.15 € for each vaccinated subject (2.33+9.61+3.21) and
17.48  € for each non-vaccinated subject
(4.66+9.61+3.21).
As per the above, the mean price of TD treatment was 3.22
€ in vaccinated subjects (after weighting 2.33 € for 93%,
and 15.15 € for the remaining 7%) and 5.55 € in non-vac-
cinated subjects (after weighting 4.66 € for 93%, and
17.48 € for the remaining 7%).
The costs associated with adverse events were not consid-
ered because vaccine trials had shown that the vaccine was
safe and adverse events, if any, would have been negligi-
ble.
The expected effectiveness in a theoretical cohort of 1000
vaccinated and non-vaccinated travellers, according to the
results of the retrospective study, is shown in Table 2.
Applied costs and analysis in theoretical cohorts of 1000
vaccinated and non-vaccinated travellers are shown in
Table 3 and Additional file 1.
In cost-effectiveness analysis, the mean cost of each vacci-
nated and non-vaccinated traveller was 57.88 € and 26.93
€, respectively. This difference correlates basically with the
price of the vaccine, given that TD treatment is cheap (par-
ticularly in its mild -and most frequent- form). Because
multivariant analysis (logistic regression models) allowed
detecting that the protective effect of vaccination against
TD is increased when trip duration is considered, uncer-
tainty adjustment with regard to this variable was per-
formed. In trips of less than 3 weeks, the mean cost per
cholera vaccinated and non-vaccinated traveller was 57.28
€ and 29.02 €, respectively. In trips of 3 weeks or more,
56.21  € and 28.04 €, respectively. Differences vs. the
whole sample were minimal.
Costs and benefits for theoretical cohorts are gathered in
Table 4. As shown, the costs of the vaccination pro-
gramme were higher than the economic benefits of the
programme from the provider perspective (net present
value of -30,958.12 €). Although vaccination does not
save money, cost-effectiveness ratios are very low.
Cost-benefit analysis of vaccine recommendation to 
tourists travelling to zones at high risk of TD
The number of prevented days of TD is the assessed effect.
Cost analysis was performed from the society perspective.
Programme costs are all those associated to the use of
health technology (likely to involve sacrifice of resources
for the patient), as well as the opportunity cost borne by
the patient on account of TD. Direct costs derived from
vaccine cost and attention at IVC, as well as the cost of TD
treatment, are included (Tables 4 and 5, and Additional
file 1). Because the travellers of our study are basically
'tourists' -with only 3.3% of patients travelling for busi-
ness-, expenses derived from TD-related lost workdays
were discarded and those derived from lost vacation days
were considered (estimated according to that described in
the 'Material and Methods' section). The costs associated
with adverse events were not considered because vaccine
trials had shown that the vaccine was safe and adverse
events, if any, would have been negligible. Given the short
term considered for assessing effects and costs, no tempo-
ral adjustment was performed.
Because vaccination benefits would depend not only on
vaccine efficacy but also on the risk of TD borne by the
travellers, uncertainty adjustment according to visited
region was performed (Table 5). The values of TD inci-
dence considered were those found in the study per-
formed to analyze vaccine effectiveness, shown in Table 1.
From the society perspective the net present value was
positive (79,260.14 €) and the cost-benefit ratio was 1.39.
Because the net present value was > 0, cost-effectiveness
Table 2: Expected incidence of health events in the theoretical cohort of 1000 travellers without and with vaccination.
Vaccine efficacy (%) TD non-vaccinated TD vaccinated Health benefits
Punctual estim. Expected cases Expected cases Absolute reduction of cases
42.6 (18.9–59.3) 366 (325–385) 211 (186–237) 155 (133–178)
Note: 95% Confidence interval are expressed between parenthesisBMC Infectious Diseases 2009, 9:65 http://www.biomedcentral.com/1471-2334/9/65
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was < 0 and therefore cost-effectiveness ratios were not
calculated (Table 4).
Preventive vaccination against TD resulted in a mean sav-
ing of 79.26 € per traveller. Depending on the destination
(Table 5), this figure would range between 48.94 € and
88.86 €, thereby justifying the indication of WC/rBS vac-
cination in subjects travelling to zones at risk of TD,
regardless of visited continent.
Discussion
Several potential limitations of this study were associated
with its design. This was a non randomized retrospective
cohort study and its findings may be affected by recall
bias. Interviewing techniques and the questionnaire qual-
ity were meticulous to minimize recall bias as it has been
suggested [24]. Data was collected in the same way and at
similar timing for both vaccinated and not vaccinated
travellers. These findings must be considered in light of
the methodologic limitations of retrospective recall.
Our study confirms the effectiveness of WC/rBS vaccine
against TD described by other authors [5,13,19,25-27]
Although relatively low, such effectiveness is in turn
important given the frequency of this multicausal pathol-
ogy called TD. The fact that the vaccine efficacy is greater
in our study than in studies by other authors could arise
from the proportion of travellers to the west coast of
Africa, where several outbreaks of cholera took place dur-
ing 2005, as well as from the higher proportion of young
adults who participated in the study, since the risk for
diarrhoea is higher among this age cohort.
The efficacy of vaccination against cholera is high (85%)
and its impact on public health is very positive [28,29].,
given the associated mortality in endemic zones and epi-
demic periods. The efficacy of WC/rBS against the ensem-
ble of TDs is logically lower because the vaccine prevents
TDs caused by Vibrio cholerae and by LT- ETEC, even by
ETEC combined with Salmonella enterica [19], but fails to
do so with the high number of remaining pathogens.
Vaccine recommendation is clear in subjects travelling to
cholera zones, as well as in those travelling to zones at risk
of TD who suffer from previous conditions where TD may
have serious consequences [5,30-32].
Convenient, however, is the economic analysis of the gen-
eral recommendation for preventive vaccination against
TD, from the perspectives of both the traveller and the
public health systems. Indeed, on account of the unceas-
ing increase in travellers, the cost of health care provided
to travellers due to travel-related diseases is increasingly
high for the different health systems. Registers and studies
measuring the expenses associated to these pathologies
are scarce. For instance, the United Kingdom has vigilance
systems of traveller diseases, and studies have been pub-
lished which evidence that the cost of travel-related ill-
nesses in the UK is in excess of € 11 million, and that, by
far, the commonest afflictions the traveller is likely to
experience are diarrhoea and vomiting [33]. Hard data are
lacking, not only on the cost effectiveness and cost benefit
of prevention and treatment of TD [31], but also on their
health situation after travel (such as how many returning
travellers are ill due to TD, what percentage need medical
care at home, and how long they are absent from work),
unit costs and total healthcare costs broken down to spe-
cific disease groups [34]. For these reasons, many assump-
tions and extrapolations have to be made that can
potentially lead to flawed estimates [34]. According to
Thomson and Booth, it must be noted that the financial
Table 3: Unit costs (base case) of estimated cost-generating events.
Type of events Cost type Estimated cost per unit (€)
Health care Care provided by IVC1 Indirect 24.90
Vaccination Vaccine Direct 32.31
TD Treatment in non-vaccinated Direct 5.552
Treatment in vaccinated Direct 3.222
Lost day of vacations Indirect 142.86
Non-vaccinated (142.86 × 3.59) Indirect 512.862
Vaccinated (142.86 × 2.57) Indirect 367.142
1 IVC: International Vacunation Centre
2Estimated cost by episode
Table 4: Costs and benefits from provider perspective and 
societal perspective
Perspective
Costs per 1000 travellers Provider Societal
Vaccination (Vaccine+IVC) 57,210.00 57,210.00
Disease without vaccination 26,931.30 214,637.01
Disease with vaccination 57,889.42 135,356.56
Net saving -30,958.12 79,280.45
Benefit-cost ratio - 1.39BMC Infectious Diseases 2009, 9:65 http://www.biomedcentral.com/1471-2334/9/65
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benefit-cost ratio of an intervention may not be the most
suitable measure of its desirability. Any possible treat-
ment will have a better benefit-cost ratio than preventive
measures. In economic terms, however, vacation days are
usually much more valued by travellers than the eco-
nomic value of the trip's price. The difficulty to quantify
the value of the absence of disease is a limiting but obvi-
ous factor in any economic analysis.
The analysis performed from the healthcare provider's
perspective has a reasonable cost (57.89 € per traveller
vaccinated with WC/rBS, vs. 26.96 € per non-vaccinated
travellers). This cost is barely relevant in the ensemble of
trip expenses and in the traveller's view to avoid a condi-
tion which, banal as it may be, is unpleasant. The cost-
benefit analysis is clearly positive, and would be even bet-
ter if analysis were extrapolated to business trips, where
'lost workdays' costs would have to be added.
Also relevant in this study is that all calculations of the
economic analysis are applied on the effectiveness data of
our observational study. Further prospective studies with
bigger samples and including traveller groups of different
profiles (visitors to friend and relatives, business people,
etc.) may add to the present assessment. A limitation to
the present study is the fact that all studied travellers came
from only two IVCs out of 52 possible centres. The size of
the sample, however, has yielded useful results. The costs
handled in the study are likely to vary among countries,
thereby only allowing approximate, non-exact extrapola-
tion.
Conclusion
In our study, the effectiveness of cholera vaccine WC/rBS
in the prevention against TD was 42.6% (TD ratio reduced
by vaccination). Moreover, the mean duration of TD in
vaccinated travellers with the disease is shortened. Accord-
ing to the cost-benefit analysis performed, the recommen-
dation for WC/rBS vaccination in subjects travelling to
zones at risk of TD is beneficial for the traveller, regardless
of trip duration and visited continent.
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